in a community clinic who underwent lab-based pretest genetic counseling, a recommendation was made to alter the genetic testing order 16% of the time. This resulted in the cancelation of testing for 9 of the 21 patients, because they either had a relative more appropriate for testing or had already tested negative. For an additional 4 of the 21 patients, the number of genes ordered was reduced, most often because of the discovery of a previously identified familial mutation after pedigree assessment by the lab-based GC. 2 The authors further posit that the mere availability of posttest lab-based genetic counseling encourages nongenetics providers to order additional, unnecessary testing beyond their scope of practice. However, in a peer-to-peer consultation model involving lab-based GCs and breast surgeons, we found that test selection was altered in 21% of cases (37 of 170) after lab-based GC consultation. A substantial proportion of modified orders resulted in a reduction in the number of genes requested. 3 Stoll et al. 1 surmise that in the posttest setting, lab-based GCs may not be "as open to discussing the potential weaknesses and failures of tests as they would be if they were independently employed." Our experience contradicts this supposition. For example, early in our lab's history we offered hereditary cancer genetic testing but at the time were unable to disambiguate certain pathogenic variants in PMS2 from pseudogene sequences. Our lab-based GCs proactively communicated this limitation, which was documented in the test reports, to both clinicians and patients, instructing those for whom PMS2 analysis was indicated to obtain genetic testing elsewhere.
The authors propose that COI concerns may be mitigated by excluding lab-based GCs from providing direct patient care. However, it is important to recognize that lab-based GCs can play a critical role in providing clinical care at this time of provider scarcity (https://www.nsgc.org/page/workforce). Lab-based GCs have the capacity to substantially alleviate GC shortages because of the unique nature of the delivery model; service is typically provided through telephone-or video-based counseling. This enables genetic counseling to be conveniently provided to patients nearly anywhere, significantly reducing wait times and improving access to services.
In our laboratory, several measures have been implemented to mitigate COI with regard to genetic counseling services. First, all of our GCs, regardless of whether they interact directly with patients, are required to annually review the NSGC Genetic Counselor Code of Ethics, as a guiding code for our profession (http://www.nsgc.org/p/cm/ld/fid = 12). Second, we disclose GC laboratory employment with our patients at three separate touch points: online at the time their appointment is scheduled, verbally at the start of the telephone genetic counseling session, and in writing as part of the clinical documentation sent to both patients and referring providers.
Third, a flat pricing structure and re-requisition to additional genes at no additional charge eliminates the possibility of "upselling." Finally, GCs who are engaged in direct patient care are paid by salary, have no quotas, and receive no commission. We propose that implementation of such practices can significantly mitigate COI, and we invite others to adopt similar measures and/or contribute additional COI-mitigating practices to this important discussion.
Rather than restrict an entire segment of our profession from providing much-needed patient care, we propose including lab-based GCs as part of the solution. As noted in Practical Genetic Counseling for the Laboratory, "Patient welfare is primary for all genetic counselors regardless of work setting." 4 We hope this discussion will act as a catalyst to further explore this issue. Such exploration will allow labbased GCs to continue addressing COI, help ameliorate the critical shortage of GCs, and continue delivering professional, patient-centered care. 
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